This site uses cookies to bring you the best experience. Find out more
Skip to main content
↑

News

Find Out The Latest

Keep in touch with exciting developments from The Oxford Science Park and its occupiers here.

Contact us on comms@oxfordsp.com if you would like to know more about any of these stories.

You can also follow us on LinkedIn  

Physiomics PARTNER study recruits first patient

Physiomics PARTNER study recruits first patient

21 Sep 2021

Physiomics plc (AIM: PYC), the consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions is pleased to announce its PARTNER study has recruited its first patient.  The study, which received formal Health Research Authority (HRA) ethics approval in December 2020 and started recruiting just this month, has been commissioned to gather data for the further development of... Read more

DR. CAROLIN BARTH JOINS MIROBIO AS CEO TO LEAD PRECISION IMMUNOLOGY COMPANY FOCUSED ON CHECKPOINT AGONIST ANTIBODIES

DR. CAROLIN BARTH JOINS MIROBIO AS CEO TO LEAD PRECISION IMMUNOLOGY COMPANY FOCUSED ON CHECKPOINT AGONIST ANTIBODIES

21 Sep 2021

DR. CAROLIN BARTH JOINS MIROBIO AS CEO TO LEAD PRECISION IMMUNOLOGY COMPANY FOCUSED ON CHECKPOINT AGONIST ANTIBODIES Former Novartis executive to lead emerging biotech with a novel precision approach to autoimmune disease, supported by recent senior appointments MiroBio is exclusively focused on checkpoint agonists produced by its unique discovery engine that comprehensively maps inhibitory checkpoint signaling pathways Clinical initiation... Read more

Exscientia in $70M collaboration for anti-virals against coronavirus & other pandemic potential viruses

Exscientia in $70M collaboration for anti-virals against coronavirus & other pandemic potential viruses

08 Sep 2021

Exscientia enters $70M collaboration to develop anti-viral therapeutics against Coronavirus and other viruses with pandemic potential Four-year agreement with Bill & Melinda Gates Foundation to discover and develop small molecule therapeutics with less susceptibility to variants and greater patient access than current approaches — Exscientia to use leading AI platform and in-house drug expertise to discover and develop five phase 1-ready... Read more

MHRA approval for Phase 1 trial of lead cancer vaccine OVM-200

MHRA approval for Phase 1 trial of lead cancer vaccine OVM-200

10 Aug 2021

Regulatory approval of OVM-200 for Phase 1 signals a significant step for Oxford Vacmedix with the first clinical trial of a cancer vaccine based on the recombinant overlapping peptide platform Oxford 10th August 2021; Oxford Vacmedix, the UK-based biopharma company focused on the development of cancer vaccines announced today that approval for a Phase 1 trial of OVM-200 has been received from the MHRA (Medicines and Healthcare products... Read more

Significant expansion of AI firm Exscientia’s headquarters at TOSP

Significant expansion of AI firm Exscientia’s headquarters at TOSP

04 Aug 2021

Significant expansion of AI firm Exscientia’s headquarters at TOSP Job creation to continue beyond 100 roles added already this year Oxford, UK, August 4 2021 – Exscientia, the clinical stage, artificial intelligence-driven pharmatech company, has announced a significant expansion of its headquarters at The Oxford Science Park (TOSP), one of the UK’s leading parks for science and technology companies. The company, which initially occupied c... Read more

The Daubeny Project

Imaginative design, inspiring spaces.

450,000 sq ft of
premium lab space
completing 2026

Discover More